The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Drugs of Bioengineered Protein Market Research Report 2025

Global Drugs of Bioengineered Protein Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1721835

No of Pages : 89

Ask Your Query

Synopsis

Bioengineered proteins?are synthesized using genetic engineering. They are also called as recombinant?protein.?Bioengineered protein drugs?are used in treatment of human injury, treatment of cancers, hormonal disorders and chronic diseases such as diabetes, asthma, heart disease etc.

The global Drugs of Bioengineered Protein market was valued at US$ 3314 million in 2023 and is anticipated to reach US$ 5001.7 million by 2030, witnessing a CAGR of 6.0% during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Drugs of Bioengineered Protein, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs of Bioengineered Protein.

Report Scope

The Drugs of Bioengineered Protein market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Drugs of Bioengineered Protein market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Drugs of Bioengineered Protein companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company

  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Novartis
  • Sanofi
  • Eli Lilly
  • Roche
  • Dr. Reddy's Laboratories
  • Abbott Laboratories
  • Amgen
  • Bayer AG
  • Biocon
  • Fresenius kabi
  • Panacea Biotec

Segment by Type

  • Monoclonal Antibodies
  • Therapeutic Proteins
  • Vaccines

Segment by Application

  • Endocrinology
  • Immunology
  • Hematology
  • Infectiology
  • Neurology
  • Oncology
  • Genetic Disorder

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drugs of Bioengineered Protein companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drugs of Bioengineered Protein Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Monoclonal Antibodies
1.2.3 Therapeutic Proteins
1.2.4 Vaccines
1.3 Market by Application
1.3.1 Global Drugs of Bioengineered Protein Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Endocrinology
1.3.3 Immunology
1.3.4 Hematology
1.3.5 Infectiology
1.3.6 Neurology
1.3.7 Oncology
1.3.8 Genetic Disorder
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Drugs of Bioengineered Protein Market Perspective (2019-2030)
2.2 Drugs of Bioengineered Protein Growth Trends by Region
2.2.1 Global Drugs of Bioengineered Protein Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Drugs of Bioengineered Protein Historic Market Size by Region (2019-2024)
2.2.3 Drugs of Bioengineered Protein Forecasted Market Size by Region (2025-2030)
2.3 Drugs of Bioengineered Protein Market Dynamics
2.3.1 Drugs of Bioengineered Protein Industry Trends
2.3.2 Drugs of Bioengineered Protein Market Drivers
2.3.3 Drugs of Bioengineered Protein Market Challenges
2.3.4 Drugs of Bioengineered Protein Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drugs of Bioengineered Protein Players by Revenue
3.1.1 Global Top Drugs of Bioengineered Protein Players by Revenue (2019-2024)
3.1.2 Global Drugs of Bioengineered Protein Revenue Market Share by Players (2019-2024)
3.2 Global Drugs of Bioengineered Protein Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Drugs of Bioengineered Protein Revenue
3.4 Global Drugs of Bioengineered Protein Market Concentration Ratio
3.4.1 Global Drugs of Bioengineered Protein Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drugs of Bioengineered Protein Revenue in 2023
3.5 Drugs of Bioengineered Protein Key Players Head office and Area Served
3.6 Key Players Drugs of Bioengineered Protein Product Solution and Service
3.7 Date of Enter into Drugs of Bioengineered Protein Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Drugs of Bioengineered Protein Breakdown Data by Type
4.1 Global Drugs of Bioengineered Protein Historic Market Size by Type (2019-2024)
4.2 Global Drugs of Bioengineered Protein Forecasted Market Size by Type (2025-2030)
5 Drugs of Bioengineered Protein Breakdown Data by Application
5.1 Global Drugs of Bioengineered Protein Historic Market Size by Application (2019-2024)
5.2 Global Drugs of Bioengineered Protein Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Drugs of Bioengineered Protein Market Size (2019-2030)
6.2 North America Drugs of Bioengineered Protein Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Drugs of Bioengineered Protein Market Size by Country (2019-2024)
6.4 North America Drugs of Bioengineered Protein Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Drugs of Bioengineered Protein Market Size (2019-2030)
7.2 Europe Drugs of Bioengineered Protein Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Drugs of Bioengineered Protein Market Size by Country (2019-2024)
7.4 Europe Drugs of Bioengineered Protein Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Drugs of Bioengineered Protein Market Size (2019-2030)
8.2 Asia-Pacific Drugs of Bioengineered Protein Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Drugs of Bioengineered Protein Market Size by Region (2019-2024)
8.4 Asia-Pacific Drugs of Bioengineered Protein Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Drugs of Bioengineered Protein Market Size (2019-2030)
9.2 Latin America Drugs of Bioengineered Protein Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Drugs of Bioengineered Protein Market Size by Country (2019-2024)
9.4 Latin America Drugs of Bioengineered Protein Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drugs of Bioengineered Protein Market Size (2019-2030)
10.2 Middle East & Africa Drugs of Bioengineered Protein Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Drugs of Bioengineered Protein Market Size by Country (2019-2024)
10.4 Middle East & Africa Drugs of Bioengineered Protein Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Company Detail
11.1.2 GlaxoSmithKline Business Overview
11.1.3 GlaxoSmithKline Drugs of Bioengineered Protein Introduction
11.1.4 GlaxoSmithKline Revenue in Drugs of Bioengineered Protein Business (2019-2024)
11.1.5 GlaxoSmithKline Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Detail
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Drugs of Bioengineered Protein Introduction
11.2.4 Johnson & Johnson Revenue in Drugs of Bioengineered Protein Business (2019-2024)
11.2.5 Johnson & Johnson Recent Development
11.3 Merck
11.3.1 Merck Company Detail
11.3.2 Merck Business Overview
11.3.3 Merck Drugs of Bioengineered Protein Introduction
11.3.4 Merck Revenue in Drugs of Bioengineered Protein Business (2019-2024)
11.3.5 Merck Recent Development
11.4 Novartis
11.4.1 Novartis Company Detail
11.4.2 Novartis Business Overview
11.4.3 Novartis Drugs of Bioengineered Protein Introduction
11.4.4 Novartis Revenue in Drugs of Bioengineered Protein Business (2019-2024)
11.4.5 Novartis Recent Development
11.5 Sanofi
11.5.1 Sanofi Company Detail
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Drugs of Bioengineered Protein Introduction
11.5.4 Sanofi Revenue in Drugs of Bioengineered Protein Business (2019-2024)
11.5.5 Sanofi Recent Development
11.6 Eli Lilly
11.6.1 Eli Lilly Company Detail
11.6.2 Eli Lilly Business Overview
11.6.3 Eli Lilly Drugs of Bioengineered Protein Introduction
11.6.4 Eli Lilly Revenue in Drugs of Bioengineered Protein Business (2019-2024)
11.6.5 Eli Lilly Recent Development
11.7 Roche
11.7.1 Roche Company Detail
11.7.2 Roche Business Overview
11.7.3 Roche Drugs of Bioengineered Protein Introduction
11.7.4 Roche Revenue in Drugs of Bioengineered Protein Business (2019-2024)
11.7.5 Roche Recent Development
11.8 Dr. Reddy's Laboratories
11.8.1 Dr. Reddy's Laboratories Company Detail
11.8.2 Dr. Reddy's Laboratories Business Overview
11.8.3 Dr. Reddy's Laboratories Drugs of Bioengineered Protein Introduction
11.8.4 Dr. Reddy's Laboratories Revenue in Drugs of Bioengineered Protein Business (2019-2024)
11.8.5 Dr. Reddy's Laboratories Recent Development
11.9 Abbott Laboratories
11.9.1 Abbott Laboratories Company Detail
11.9.2 Abbott Laboratories Business Overview
11.9.3 Abbott Laboratories Drugs of Bioengineered Protein Introduction
11.9.4 Abbott Laboratories Revenue in Drugs of Bioengineered Protein Business (2019-2024)
11.9.5 Abbott Laboratories Recent Development
11.10 Amgen
11.10.1 Amgen Company Detail
11.10.2 Amgen Business Overview
11.10.3 Amgen Drugs of Bioengineered Protein Introduction
11.10.4 Amgen Revenue in Drugs of Bioengineered Protein Business (2019-2024)
11.10.5 Amgen Recent Development
11.11 Bayer AG
11.11.1 Bayer AG Company Detail
11.11.2 Bayer AG Business Overview
11.11.3 Bayer AG Drugs of Bioengineered Protein Introduction
11.11.4 Bayer AG Revenue in Drugs of Bioengineered Protein Business (2019-2024)
11.11.5 Bayer AG Recent Development
11.12 Biocon
11.12.1 Biocon Company Detail
11.12.2 Biocon Business Overview
11.12.3 Biocon Drugs of Bioengineered Protein Introduction
11.12.4 Biocon Revenue in Drugs of Bioengineered Protein Business (2019-2024)
11.12.5 Biocon Recent Development
11.13 Fresenius kabi
11.13.1 Fresenius kabi Company Detail
11.13.2 Fresenius kabi Business Overview
11.13.3 Fresenius kabi Drugs of Bioengineered Protein Introduction
11.13.4 Fresenius kabi Revenue in Drugs of Bioengineered Protein Business (2019-2024)
11.13.5 Fresenius kabi Recent Development
11.14 Panacea Biotec
11.14.1 Panacea Biotec Company Detail
11.14.2 Panacea Biotec Business Overview
11.14.3 Panacea Biotec Drugs of Bioengineered Protein Introduction
11.14.4 Panacea Biotec Revenue in Drugs of Bioengineered Protein Business (2019-2024)
11.14.5 Panacea Biotec Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock